A case of fatalPemphigus Vulgaris in association with beta interferon and interleukin-2 therapy
- 15 May 1989
- Vol. 63 (10) , 2005-2007
- https://doi.org/10.1002/1097-0142(19890515)63:10<2005::aid-cncr2820631023>3.0.co;2-p
Abstract
Beta interferon (β-IFN) and interleukin-2 (IL-2) have been utilized in experimental cancer therapy because of their effects on the immune system. We report here a patient treated with IL-2 and β-IFN who rapidly developed an immune-mediated, bullous exfoliative dermatitis and who ultimately died. Various etiologic mechanisms are proposed.This publication has 27 references indexed in Scilit:
- The association of pemphigus with thymoma or malignancy: a critical reviewBritish Journal of Dermatology, 2006
- Thyroid Autoimmunity in Patients on Long Term Therapy with Leukocyte-Derived Interferon*Journal of Clinical Endocrinology & Metabolism, 1986
- Alpha-Interferon and Immune Hemolytic AnemiaAnnals of Internal Medicine, 1986
- Clinical toxicity of interferons in cancer patients: a review.Journal of Clinical Oncology, 1986
- Nephrotic syndrome during treatment with interferon.BMJ, 1985
- Deficiency of Interleukin-2 Production and Interleukin-2 Receptor Expression on Peripheral Blood Leukocytes after Phytohemagglutinin Stimulation in PemphigusJournal of Investigative Dermatology, 1984
- Cutaneous vasculitis associated with interferonEuropean Journal of Cancer and Clinical Oncology, 1983
- Pemphigus Vulgaris and Lymphoma in a Patient With SclerodermaSouthern Medical Journal, 1979
- Lymphomatoid Granulomatosis After Immunosuppression for PemphigusArchives of Dermatology, 1978
- Pemphigus vulgaris and internal malignancyCancer, 1974